Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
about
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerClinical Translation of Nanomedicine.Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments.Combination therapy with gemcitabine and nab-paclitaxel for locally advanced unresectable pancreatic cancer.Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumorsSuccessful chemotherapy with nab-Paclitaxel in a heavily treated non-small cell lung cancer patient: a case report.Clinical trials and progress with paclitaxel in ovarian cancerSafety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.Nab-paclitaxel (abraxane)-based chemotherapy to treat elderly patients with advanced non-small-cell lung cancer: a single center, randomized and open-label clinical trial.DCE-MRI-Derived Parameters in Evaluating Abraxane-Induced Early Vascular Response and the Effectiveness of Its Synergistic Interaction with Cisplatin.Update on taxane development: new analogs and new formulationsA retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma.A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusionNab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.Weekly intravenous nanoparticle albumin-bound paclitaxel for elderly patients with stage IV non-small-cell lung cancer: a series of 20 cases.Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer.Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas.New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy.Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent.Docetaxel in the treatment of advanced non-small-cell lung cancer.Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.Biodistribution and renal clearance of biocompatible lung targeted poly(ethylene glycol) (PEG) nanogel aggregates.First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.Nanomedicine for the management of lung and blood diseases.Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.Emerging mitotic inhibitors for non-small cell carcinoma.Emerging protein kinase inhibitors for non-small cell lung cancer.Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung CancerInterstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer.A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancernab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.
P2860
Q26766180-2C284FEF-81AC-4873-8103-254112601B23Q28396304-90580240-F87E-4EC7-98C9-BB560C9D941FQ30355939-0B7F47C0-3BF4-42E5-A2B5-8D27CB9262F9Q33409023-7981DD09-ADC0-48FB-8A14-65D222EAD63EQ33412928-1E9789B3-DEF5-4730-8A9A-7C6B97DB18D1Q33423320-878E848B-BFC8-448A-B5AE-1AAC4FB719F0Q33633684-AEB5E3AD-9A4E-4242-8E57-A7A1193ED881Q33748302-AEA9FA67-58B0-45CB-9D06-10DC51605256Q33813555-0C6AA7A3-782C-43A2-AD72-70E273C8B271Q33822801-F052970C-25CA-4BAA-81FA-E80CD0C47618Q33937901-934A9B17-94E7-427E-A5A8-94834C90B620Q34510070-B6BAA653-B246-42AF-9630-1A490BE8B88EQ34965672-F4DCAD2A-DBC9-4C6D-8C0C-ADC55B5F25FBQ35538742-92B1DC46-63DF-41EF-A3DC-F712D3915479Q36134678-14E8BE6F-20A5-4204-B161-479DFE440297Q36470377-A8BE552F-64AD-4382-8508-1BCC9763F353Q36617748-732A545E-EAFE-436A-88B9-C8A49C9E9F04Q36635810-C9C167C5-6B4E-49D6-B086-9A8C723CD113Q36661727-E35E2535-C7FA-4695-BC29-3FD1B06A9E63Q36680050-7246F654-0684-40CE-9577-AFA916EBAF15Q36767660-19CC1148-F46F-4279-B60C-538B9E408EEFQ36927640-672B5400-9D16-40B0-9197-06BD1E591180Q37080517-33E6A26E-0C14-46EE-80EE-FD6BA7149A45Q37119741-2BE17E91-C9C8-41BB-848E-9137E3292348Q37242661-E028F1A3-CBFB-4B2A-A2F6-083D8A4F8CB1Q37361227-4D098DBA-A27C-4902-B9A0-0B4C5891F5BEQ37382745-F87C01BB-810C-4EBB-801C-EA00D86DF29CQ37419857-82B000BA-4B22-4386-B4A5-BC591AB2A2E3Q37426681-0454B369-C6A8-4C4B-83CF-ED800C94A131Q37768460-24B0A003-B7FC-4F63-8740-1750433E5A66Q37875561-A5DFFDEC-A247-4FC5-964B-98C9A30BE729Q38085327-03AB4826-D952-4F93-A5DE-58E758C683FBQ38172608-F73A4D03-074B-416B-96EC-3CBAB378A102Q38258744-2B91EFC3-D24A-479C-A3AA-83ADD58F2B2CQ38946259-93E8303F-DECC-424C-8BF2-535F71B03154Q41536996-807A74FA-F5F2-42B3-98BF-FF1574D9090FQ41601086-DCB8603A-E018-4846-97DE-7237F9920203Q42689822-31E31A97-AADB-4EDE-8630-60D46B332D91Q42992197-9A1A79B8-64F9-4281-AFB7-1B444EFE8553Q43620697-81613FAD-FD59-4B87-A814-F1FEC87BA252
P2860
Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@en
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@nl
type
label
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@en
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@nl
prefLabel
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@en
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@nl
P2093
P921
P356
P1476
Phase I/II trial of weekly int ...... IV non-small-cell lung cancer.
@en
P2093
Christopher G Azzoli
Gloria Chia
Gregory J Riely
John Fiore
Kenneth K Ng
Martin Brower
Michael J Hawkins
Naiyer A Rizvi
Robert Heelan
Vincent A Miller
P304
P356
10.1200/JCO.2007.10.8605
P407
P50
P577
2008-02-01T00:00:00Z